Articles, guides, and regulatory updates from our community.
A landmark 2025 BMJ network meta-analysis comparing 19 obesity drugs across 262 trials reveals key trade-offs between weight loss, side effects, and heart health.
By Peptide Association Research Team
New research across 85 trials finds incretin-based therapies modestly reduce blood pressure and lower mortality in adults with obesity. Read the evidence.
By Peptide Association Research Team
New research explores retatrutide's role in CKM syndrome, showing significant weight loss, glycemic control, and cardiorenal benefits in Phase 2 trials.
By Peptide Association Research Team
New research on retatrutide shows promising weight loss and metabolic results. Learn what the 2026 clinical review found about this triple hormone receptor agonist.
By Peptide Association Research Team